Skal hjerte- Og karsykdommer behandles med antibiotika?

Tidsskrift for den Norske Laegeforening

Volumn 118, Issue 26, 1998, Pages 4115-4116

  Ånestad, Gabriel ^a   Scheel, Olaf ^a,b  

^a NORWEGIAN INSTITUTE OF PUBLIC HEALTH   (Norway)

^b Buskerud Sentralsykehus   (Norway)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIINFECTIVE AGENT;

ARTICLE; CARDIOVASCULAR DISEASE; CHLAMYDIASIS; CHLAMYDOPHILA PNEUMONIAE; HUMAN; ISOLATION AND PURIFICATION; MICROBIOLOGY;

ANTI-BACTERIAL AGENTS; CARDIOVASCULAR DISEASES; CHLAMYDIA INFECTIONS; CHLAMYDOPHILA PNEUMONIAE; HUMANS;

EID: 0032582363     PISSN: 00292001     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (20)

1. Coutts WE, Davila M. Lymphogranuloma venerum as a possible cause of arterio-sclerosis and other arterial conditions. J Trop Med Hyg 1945; 48: 46-51.
2. Bang HO, Dyerberg J, Nielsen AB. Plasma lipid and lipoprotein pattern in Greenlandic west-coast eskimos. Lancet 1971; 1: 1143-6.
3. Johansson L, Drevon CA, Bjørneboe G-EA. The Norwegian diet during the last hundred years in relation to coronary heart disease. Bur J Clin Nutr 1996; 50: 277-83.
4. Esrey KL, Joseph L, Grover SA. Relationship between dietary intake and coronary heart disease mortality: lipid research clinics prevalence follow-up study. J Clin Epidemiol 1996; 49: 211-6.
5. Rosén M, Thelle DS. Cardiovascular diseases in the Nordic countries - distribution and trends of morbidity, mortality and risk factors. I: Health statistics in the Nordic countries 1994. København: Nordisk Medicinalstatistiske Komité, 1996: 176-96.
6. Mackenbach JP, Kunst AE, Cavelaars EJM, Groenhof F, Guerts JJM. Socioeconomic inequalities in morbidity and mortality in western Europe. Lancet 1997; 349: 1655-9.
7. Jenum AK, Thelle DS, Stensvold I, Hjermann I. Regionale ulikheter i sykdomsrisiko i Oslo. Røyke- og mosjonsvaner, kroppsmasseindeks, blodlipidnivå og blodtrykk blant 40-åringer 1985-88. Tidsskr Nor Lægeforen 1998; 118: 23-7.
8. Saikku P, Leinonen M, Mattila K, Ekman MR, Nieminen MS, Mäkelä PH et al. Serologic evidence of an association of a novel Chlamydia, TWAR, with chronic coronary heart disease and acute myocardial infarction. Lancet 1988; 2: 983-5.
9. Danesh J, Collins R, Peto R. Chronic infections and coronary heart disease: is there a link? Lancet 1997; 350: 430-6.
10. Andersen JJ. Chlamydia pneumoniae og aterosklerose. Ugeskr Læger 1997; 159: 5503-7.
11. Ramirez JA. Isolation of Chlamydia pneumoniae from the coronary artery of a patient with coronary atherosclerosis. Ann Intern Med 1996; 125: 979-82.
12. Jackson LA, Campbell LA, Kuo CC, Rodriguez DI, Lee A. Grayston JT. Isolation of Chlamydia pneumoniae from a carotid endarterectomy specimen. J Infect Dis 1997; 176: 292-5.
13. Gaydos CA, Summersgill JT, Sahney NN, Ramirez JA, Quinn TC. Replication of Chlamydia pneumoniae in vitro in human macrophages, endothelial cells, and aortic artery smooth muscle cells. Infect Immun 1996; 64: 1614-20.
14. Moazed TC, Kuo CC, Grayston JT, Campbell LA. Murine models of Chlamydia pneumoniae infection and atherosclerosis. J Infect Dis 1997; 175: 883-90.
15. Gupta S, Leatham EW, Carrington D, Mendall MA, Kaski JC, Camm AJ. Elevated Chlamydia pneumoniae antibodies, cardiovascular events, and azithromyc in male survivors of myocardial infarction. Circulation 1997; 96: 404-7.
16. Gurfinkel E, Bozovich G, Daroca A, Beck E, Mautner B. Randomised trial of roxithromycin in non-Q-vave coronary syndromes: Roxis pilot study. Lancet 1997; 350: 404-7.
17. Ånestad G, Scheel O, Hungnes O. Chronic infections and coronary heart disease. Lancet 1997; 350: 1028.
18. Grayston JT. Antibiotic treatment of Chlamydia pneumoniae for secondary prevention of cardiovascular events. Circulation 1998; 97: 1669-70.
19. Hammerschlag MR. Current knowledge of Chlamydia pneumoniae and atherosclerosis. Eur J Clin Microbiol Infect Dis 1998; 17: 305-8.
20. Sinisalo J, Mattila K, Nieminen MS, Valtonen V, Syrjälä M, Sundberg S et al. The effect of prolonged doxycycline therapy on Chlamydia pneumoniae serological markers, coronary heart disease risk factors and forearm basal nitric oxide production. J Antimicrob Chemother 1998; 41: 85-92.